U.S. markets closed
  • S&P 500

    3,818.83
    -2.72 (-0.07%)
     
  • Dow 30

    31,029.31
    +82.32 (+0.27%)
     
  • Nasdaq

    11,177.89
    -3.65 (-0.03%)
     
  • Russell 2000

    1,719.37
    -19.47 (-1.12%)
     
  • Crude Oil

    109.31
    -2.45 (-2.19%)
     
  • Gold

    1,820.40
    -0.80 (-0.04%)
     
  • Silver

    20.68
    -0.13 (-0.61%)
     
  • EUR/USD

    1.0445
    -0.0080 (-0.76%)
     
  • 10-Yr Bond

    3.0930
    -0.1130 (-3.52%)
     
  • GBP/USD

    1.2120
    -0.0065 (-0.53%)
     
  • USD/JPY

    136.6580
    +0.5300 (+0.39%)
     
  • BTC-USD

    20,316.98
    +65.35 (+0.32%)
     
  • CMC Crypto 200

    438.05
    -1.61 (-0.37%)
     
  • FTSE 100

    7,312.32
    -11.09 (-0.15%)
     
  • Nikkei 225

    26,804.60
    -244.87 (-0.91%)
     

Recap: Blueprint Medicines Q2 Earnings

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results.

Quarterly Results

Earnings per share fell 11.76% over the past year to ($2.28), which missed the estimate of ($2.14).

Revenue of $8,343,000 up by 63.27% year over year, which beat the estimate of $6,600,000.

Outlook

Blueprint Medicines hasn't issued any earnings guidance for the time being.

Blueprint Medicines hasn't issued any revenue guidance for the time being.

Details Of The Call

Date: Jul 30, 2020

View more earnings on BPMC

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/m82wn2p5

Recent Stock Performance

Company's 52-week high was at $101.76

52-week low: $43.29

Price action over last quarter: Up 22.55%

Company Overview

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.